Jeffrey I Weitz1, John Strony1, Walter Ageno1, David Gailani1, Elaine M Hylek1, Michael R Lassen1, Kenneth W Mahaffey1, Ravi S Notani1, Robin Roberts1, Annelise Segers1, Gary E Raskob1. 1. From the Thrombosis and Atherosclerosis Research Institute and McMaster University (J.I.W., R.R.) - both in Hamilton, ON, Canada; Janssen Research and Development, Raritan, NJ (J.S., R.S.N.); the University of Insubria, Varese, Italy (W.A.); Vanderbilt University Medical Center, Nashville (D.G.); Boston University School of Medicine, Boston (E.M.H.); Gildhøj Private Hospital, Copenhagen (M.R.L.); Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA (K.W.M.); International Trial Expertise Advisory and Services, Amsterdam (A.S.); and Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.).
Abstract
BACKGROUND: Factor XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism may be more effective and result in less bleeding than conventional anticoagulants. Additional data are needed regarding the efficacy and safety of milvexian, an oral factor XIa inhibitor. METHODS: In this parallel-group, phase 2 trial, we randomly assigned 1242 patients undergoing knee arthroplasty to receive one of seven postoperative regimens of milvexian (25 mg, 50 mg, 100 mg, or 200 mg twice daily or 25 mg, 50 mg, or 200 mg once daily) or enoxaparin (40 mg once daily). The primary efficacy outcome was venous thromboembolism (which was a composite of asymptomatic deep-vein thrombosis, confirmed symptomatic venous thromboembolism, or death from any cause). The principal safety outcome was bleeding. RESULTS: Among the patients receiving milvexian twice daily, venous thromboembolism developed in 27 of 129 (21%) taking 25 mg, in 14 of 124 (11%) taking 50 mg, in 12 of 134 (9%) taking 100 mg, and in 10 of 131 (8%) taking 200 mg. Among those receiving milvexian once daily, venous thromboembolism developed in 7 of 28 (25%) taking 25 mg, in 30 of 127 (24%) taking 50 mg, and in 8 of 123 (7%) taking 200 mg, as compared with 54 of 252 patients (21%) taking enoxaparin. The dose-response relationship with twice-daily milvexian was significant (one-sided P<0.001), and the 12% incidence of venous thromboembolism with twice-daily milvexian was significantly lower than the prespecified benchmark of 30% (one-sided P<0.001). Bleeding of any severity occurred in 38 of 923 patients (4%) taking milvexian and in 12 of 296 patients (4%) taking enoxaparin; major or clinically relevant nonmajor bleeding occurred in 1% and 2%, respectively; and serious adverse events were reported in 2% and 4%, respectively. CONCLUSIONS: Postoperative factor XIa inhibition with oral milvexian in patients undergoing knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding. (Funded by Bristol Myers Squibb and Janssen Research and Development; AXIOMATIC-TKR ClinicalTrials.gov number, NCT03891524.).
BACKGROUND: Factor XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism may be more effective and result in less bleeding than conventional anticoagulants. Additional data are needed regarding the efficacy and safety of milvexian, an oral factor XIa inhibitor. METHODS: In this parallel-group, phase 2 trial, we randomly assigned 1242 patients undergoing knee arthroplasty to receive one of seven postoperative regimens of milvexian (25 mg, 50 mg, 100 mg, or 200 mg twice daily or 25 mg, 50 mg, or 200 mg once daily) or enoxaparin (40 mg once daily). The primary efficacy outcome was venous thromboembolism (which was a composite of asymptomatic deep-vein thrombosis, confirmed symptomatic venous thromboembolism, or death from any cause). The principal safety outcome was bleeding. RESULTS: Among the patients receiving milvexian twice daily, venous thromboembolism developed in 27 of 129 (21%) taking 25 mg, in 14 of 124 (11%) taking 50 mg, in 12 of 134 (9%) taking 100 mg, and in 10 of 131 (8%) taking 200 mg. Among those receiving milvexian once daily, venous thromboembolism developed in 7 of 28 (25%) taking 25 mg, in 30 of 127 (24%) taking 50 mg, and in 8 of 123 (7%) taking 200 mg, as compared with 54 of 252 patients (21%) taking enoxaparin. The dose-response relationship with twice-daily milvexian was significant (one-sided P<0.001), and the 12% incidence of venous thromboembolism with twice-daily milvexian was significantly lower than the prespecified benchmark of 30% (one-sided P<0.001). Bleeding of any severity occurred in 38 of 923 patients (4%) taking milvexian and in 12 of 296 patients (4%) taking enoxaparin; major or clinically relevant nonmajor bleeding occurred in 1% and 2%, respectively; and serious adverse events were reported in 2% and 4%, respectively. CONCLUSIONS: Postoperative factor XIa inhibition with oral milvexian in patients undergoing knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding. (Funded by Bristol Myers Squibb and Janssen Research and Development; AXIOMATIC-TKR ClinicalTrials.gov number, NCT03891524.).
Authors: Ophira Salomon; David M Steinberg; Michal Zucker; David Varon; Ariella Zivelin; Uri Seligsohn Journal: Thromb Haemost Date: 2010-11-05 Impact factor: 5.249
Authors: Jeffrey I Weitz; Rupert Bauersachs; Bastian Becker; Scott D Berkowitz; Maria C S Freitas; Michael R Lassen; Carola Metzig; Gary E Raskob Journal: JAMA Date: 2020-01-14 Impact factor: 56.272
Authors: Benjamin A Steinberg; Haiyan Gao; Peter Shrader; Karen Pieper; Laine Thomas; A John Camm; Michael D Ezekowitz; Gregg C Fonarow; Bernard J Gersh; Samuel Goldhaber; Sylvia Haas; Werner Hacke; Peter R Kowey; Jack Ansell; Kenneth W Mahaffey; Gerald Naccarelli; James A Reiffel; Alexander Turpie; Freek Verheugt; Jonathan P Piccini; Ajay Kakkar; Eric D Peterson; Keith A A Fox Journal: Am Heart J Date: 2017-08-24 Impact factor: 4.749
Authors: Harry R Büller; Claudette Bethune; Sanjay Bhanot; David Gailani; Brett P Monia; Gary E Raskob; Annelise Segers; Peter Verhamme; Jeffrey I Weitz Journal: N Engl J Med Date: 2014-12-07 Impact factor: 91.245
Authors: Peter Verhamme; B Alexander Yi; Annelise Segers; Janeen Salter; Daniel Bloomfield; Harry R Büller; Gary E Raskob; Jeffrey I Weitz Journal: N Engl J Med Date: 2021-07-19 Impact factor: 91.245
Authors: Saket Sanghai; Cecillia Wong; Ziyue Wang; Pia Clive; Wenisa Tran; Molly Waring; Robert Goldberg; Robert Hayward; Jane S Saczynski; David D McManus Journal: J Am Heart Assoc Date: 2020-03-09 Impact factor: 5.501